Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Neurology

Volumn 50, Issue 3, 1998, Pages 701-708

  Johnson, Kenneth P ^a,k   Brooks, B R ^b   Cohen, J A ^c   Ford, C C ^d   Goldstein, J ^e   Lisak, R P ^f   Myers, L W ^g   Panitch, H S ^a   Rose, J W ^h   Schiffer, R B ^l   Vollmer, T ^e   Weiner, L P ⁱ   Wolinsky, J S ^j  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; PLACEBO;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; HEART PALPITATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SINGLE BLIND PROCEDURE; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 6844254570     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.3.701     Document Type: Article

References (19)

1. Bernard CCA, Mandel TE, Mackay IR. Experimental models of human autoimmune disease: overview and prototypes. In: Rose NR, Mackay IR, eds. The autoimmune diseases II. San Diego: Academic Press, 1992:47-106.
2. Ben-Nun A, Mendel I, Bakimer R, et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol 1996;243(Suppl 1):S14-S22.
3. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979;123:2156-2160.
4. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 1994;91:4872-4876.
5. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of copolymer 1 in exacerbating- remitting multiple sclerosis. N Engl J Med 1987;317:408-414.
6. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41: 533-539.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
8. Johnson KP, U.S. Phase III Copolymer 1 Study Group. Copolymer 1: multicenter multiple sclerosis trial extension shows improved effects on relapse rate and disability. Ann Neurol 1995;38:971. Abstract.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
12. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-1428.
13. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci 1996;135:1-9.
14. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group. Ann Neurol 1994;36:S108-S112.
15. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 1996;39:285-294.
17. Johnson KP, the U.S. Phase III Copolymer I Study Group, Teitelbaum D, et al. Antibodies to copolymer 1 do not interfere with its clinical effect. Ann Neurol 1995;38:973. Abstract.
18. 2. Ann Neurol 1996;40: 518. Abstract.
19. Teitelbaum D, Brenner T, Sela M, Arnon T. Antibodies to copolymer 1 do not interfere with its therapeutic effect. Eur J Neurol 1996;3:134. Abstract.